Bristol-myers Squibb Pharma Company

Bristol-myers Squibb Compnay

The Dupont Merck Pharmaceutical Company

Other

E.i. Dupont De Nemours and Company

Dupont Pharmaceuticals Company

Dupont Pharmaceuticals, Inc.

Bristol-myers Squibb Pharma Corporation

Soo Sung Ko

John V Duncia

Dean A Wacker

George V DeLucca

Joseph B Santella

Douglas G Batt

Anurag S Srivastava

George V Delucca

Daniel S Gardner

Ui Tae Kim

Robert J Cherney

Scott Hunter Watterson

Charles Malcolm Langevine

Michael G Yang

Percy H Carter

Qingjie Liu

Myra Beaudoin Bertrand

Joseph Anthony Tino

Paul Steven Watson

Michael A Galella

Qing Shi

James M Trzaskos

Jagabandhu Das

James Russell Pruitt

Changsheng Zheng

Richard Gerald Wilde

Ronald L Magolda

Jeffrey W Corbett

Paul R Johnson

Cheryl McArdle Clark

James L Gaylor

Simon H Stam

Wenqing Yao

T G Murali Dhar

Alaric J Dyckman

John T Hynes

Hai-Yun Xiao

Hui-Yin Li

Steven P Seitz

Prabhakar Kondaji Jadhav

Zili Xiao

George A Boswell

Mona Patel

Anthony J Cocuzza

Jeffrey T Billheimer

George V De Lucca

Rodney Lawrence Parsons, Jr

Jeffrey G Varnes

Hollis S Kezar, Iii

Indawati DeLucca

Abdul Ezaz Mutlib

David Donald Christ

Joseph B Santella Iii

Jay Andrew Markwalder

Charles M Langevine

TG Murali Dhar

Anurag Srivastava

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: Ris F, Cl, &#x2014;CN, or &#x2014;CH; Ris Cl or &#x2014;CH; Ris &#x2014;C(CH)OH or &#x2014;CHCHOH; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CH, and/or &#x2014;OCH; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: Ris &#x2014;C(CH)2OH, &#x2014;NHC(=0)C(CH), &#x2014;N(CH3)2, or &#x2014;CHR; Ris CI or &#x2014;CH; Ris H, F, or &#x2014;CH; Ris H or &#x2014;CH; Ris H, F, CI, or &#x2014;OCH3 Ris H or F; and Rd is &#x2014;OH, &#x2014;OCH3, &#x2014;NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Carbazole carboxamide compounds

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X, X, X, W, Q, Q, and Gare defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Tricyclic heterocyclic compounds

Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted oxadiazole compounds

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

Cyclic derivatives as modulators of chemokine receptor activity

This invention relates generally to modulators of chemokine receptor activity having unexpected combination of desirable pharmacological properties. Pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases, particularly diabetes, Crohn's disease, atherosclerosis, and multiple sclerosis, along with methods of preparing compounds and intermediates therefor. Metabolites of active compounds are also provided herein, pharmaceutical compositions and use thereof are also provided.

The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.

N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Heterocyclic piperidines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity

Growing community of inventors

Hockessin, DE, United States of America

Soo Sung Ko